Global Burden of Disease of Multiple Myeloma in China from 1990 to 2021

This study aims to provide an updated disease burden of multiple myeloma in China from 1990 to 2021. We used data from Global Burden of Disease Database (GBD) 2021 to estimate age-, sex-, and province-specific incidence, mortality, prevalence, disability-adjusted life-years (DALYs), years of life lost (YLLs), years lived with disability (YLDs) of 34 provincial administrative units in China. There were estimated 17250 new cases and 12984 cases of death of MM in China in 2021. The age-standardized incidence, mortality and prevalence rate per 100,000 population were 0.8, 0.6 and 2.2, respectively. The highest disease burden were observed in provinces with top per capita GDP. From 1990 to 2021, the estimated age-standardized incidence and mortality increased by 3.1% and 2.2%, in parallel with an unproportioned increase of age-standardized prevalence rate of MM by 5.8%, indicating improved treatment efficacy and extended patient survival in MM. The age-standardized DALY rate increased by 2.2%. There had seen a more rapid increase in incidence among younger populations compare to the eldly. It was estimated that 5.47% of all death MM cases in 2021 were attributable to high BMI. During the past three decades, the disease burden of MM in China continued to increase. This study provided comprehensive estimates that can potentially inform efforts toward management of MM in China.

No relevant conflicts of interest to declare.